(Q34512351)

2 August 2017

title

Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine (English)

1 reference

2 August 2017

Eichelbaum M

1

1 reference

2 August 2017

Bertilsson L

series ordinal

2

1 reference

2 August 2017

Säwe J

series ordinal

3

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 March 1983

1 reference

British Journal of Clinical Pharmacology

2 August 2017

published in

1 reference

2 August 2017

volume

15

1 reference

2 August 2017

issue

3

1 reference

2 August 2017

page(s)

317-321

1 reference

Differential induction of antipyrine metabolism by rifampicin.

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Pharmacokinetics and metabolism of antipyrine (phenazone) after intravenous and oral administration.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Differential effects of enzyme induction on antipyrine metabolite formation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Defective oxidation of drugs: pharmacokinetic and therapeutic implications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Family study of antipyrine clearance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Genetic and environmental factors affecting drug disposition in man

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Factors influencing antipyrine elimination

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Polymorphisms of Oxidation at Carbon Centers of Drugs and Their Clinical Significance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

The antipyrine test in clinical pharmacology: Conceptions and misconceptions

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Polymorphic hydroxylation of Debrisoquine in man.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1427783

Genetic Control of Drug Levels in Man: Antipyrine

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1983.TB01505.X

Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1983.TB01505.X

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1111%2FJ.1365-2125.1983.TB01505.X

Deficient metabolism of debrisoquine and sparteine

21 January 2018

1 reference

12 December 2020

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

12 December 2020

Toxicological implications of polymorphic drug metabolism

1 reference

12 December 2020

Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation

1 reference

12 December 2020

Phenformin-induced lacticacidosis associated with impaired debrisoquine hydroxylation

1 reference

12 December 2020

Hydroxylation of debrisoquine in patients with lacticacidosis after phenformin

1 reference

12 December 2020

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

12 December 2020

Influence of the Genetically Controlled Deficiency in Debrisoquine Hydroxylation on Antipyrine Metabolite Formation

1 reference

12 December 2020

HPLC Determination of Antipyrine Metabolites

1 reference

12 December 2020

Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time

1 reference

12 December 2020

Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking

1 reference

12 December 2020

10.1111/J.1365-2125.1983.TB01505.X

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference